Investment analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Down 1.9 %
NASDAQ GLMD opened at $0.39 on Wednesday. The stock’s 50-day simple moving average is $0.36 and its two-hundred day simple moving average is $0.38. Galmed Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $7.80. The company has a market capitalization of $1.98 million, a price-to-earnings ratio of -0.12 and a beta of 0.87.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- What is the S&P 500 and How It is Distinct from Other Indexes
- Hasbro’s Management Made All the Right Calls This Quarter
- Transportation Stocks Investing
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What is a buyback in stocks? A comprehensive guide for investors
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
